Can the pharmaceutical industry reduce attrition rates?
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Part of the attrition may be due to low animal-to-human translational success rates; the so-called “translational failure” [3].”
From Animal to human translation: a systematic scoping review of reported concordance rates (2019) · cites this paper as [3]
In the citing paper
“Even so, late-stage attritions are still frequent [11].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [11]
In the citing paper
“Inhibition of the hERG channel can be an indicator of the APD prolongation and cardiotoxicity in early stages of drug development [11].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [11]
In the citing paper
“Less than 20 years ago, developing a drug took ~12 years, cost under a billion dollars, and the biggest challenges were failures due to efficacy or toxicity-induced attrition2.”
From Exploiting machine learning for end-to-end drug discovery and development (2019) · cites this paper as [2]
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265 · cited 1×
“In 2001, the costs of discovering and developing a drug were of the order of US d804 millio”
BackgroundRoberds, S. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1317 · Cited by 705 · cited 1×
“We have, in a similar manner, provided very strong evidence that inhibition of β-secretase inhibits the production of amyloid-β in knockout mic”
ResultGowen, M., Lazner, F., Dodds, R., Kapadia, R., Feild, J., Tavaria, M., Bertoncello, I., Drake, F., Zavarselk, S., Tellis, I., et al. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.10.1654 · Cited by 490
Self-citationMa, P., & Zemmel, R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd884 · Cited by 174
Booth, B. L., Glassman, R. H., & Ma, P. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1158 · Cited by 84
An animal model for pycnodysostosis: the role of cathepsin K in bone remodelling
Lazner, F., Gowen, M., & Kola, I. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01563-4 · Cited by 18 · cited 1×
“and that cathepsin K is involved in bone resorption (further compelling proof of mechanism is provided by humans with pycnodysostosi”
BackgroundSelf-citation2003 approvals: a year of innovation and upward trends
Frantz, S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1327 · Cited by 15
Research works printed but not linked: 4
- Kola, I. & Rafferty, M. New technologies that may impact drug discovery in the 5–10 year timeframe workshop. 2002 Biomed. Expo Ann Arbor Michigan (data derived from Prous Science, Drugs News Prospect (2002).
- Fearn, C. J. IMS Health. The World Pharmaceutical Market Presented at the Strategic Management Review, Australia, 19–20 June (2002).
- Benjamin, G. A. & Lumley, C. E. Industry Success Rates 2003 Including Trends in Success Rates CMR Report Number 03–202 R (CMR International Surrey, UK, 2003).
- Van den Haak, M. A., Palachandran, J. & Benjamin, G. A. Performance Metrics in Global Pharmaceutical R&D, Company specific review 2002 for Merck & Co. (CMR International, Surrey, UK, 2003).
Cited by
Items 901–1,000 of 1,025
Building a conducive environment for life science-based entrepreneurship and industry clusters
Ahn, M. J., & Meeks, M. D. (2007) · Journal of Commercial Biotechnology · doi:10.1057/palgrave.jcb.3050076 · Cited by 58
“For the drugs that progress into human clinical trials the overall attrition rates is 11%, with oncology at 5% (although biopharmaceuticals tend to have a lower overall clinical approval success rate compared to traditional pharmaceutical firm products) (PhRMA, 2006; Kola and Lands, 2004).”
BackgroundAnti-infective monoclonal antibodies: perils and promise of development
Reichert, J. M., & Dewitz, M. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1987 · Cited by 58
van den Broek, S. L., Shalgunov, V., & Herth, M. M. (2022) · Biomaterials Advances · doi:10.1016/j.bioadv.2022.213125 · Cited by 52
Single-cell mapping of lipid metabolites using an infrared probe in human-derived model systems
Bai, Y., Camargo, C. M., Glasauer, S. M. K., Gifford, R., Tian, X., Longhini, A. P., & Kosik, K. S. (2024) · Nature Communications · doi:10.1038/s41467-023-44675-0 · Cited by 64
The role of translational bioinformatics in drug discovery
Buchan, N. S., Rajpal, D. K., Webster, Y., Alatorre, C., Gudivada, R. C., Zheng, C., Sanséau, P., & Koehler, J. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.03.002 · Cited by 63
Mahida, S., Hogarth, A. J., Cowan, C., Tayebjee, M. H., Graham, L., & Pepper, C. (2013) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-013-9779-5 · Cited by 60
Understanding the Molecular Properties and Metabolism of Top Prescribed Drugs
Zhong, H., Mashinson, V., Woolman, T. A., & Zha, M. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990034 · Cited by 57
Improving the Solubility of Lenalidomide via Cocrystals
Song, J.-X., Yan, Y., Yao, J., Chen, J., & Lu, T. (2014) · Crystal Growth & Design · doi:10.1021/cg500327s · Cited by 57
McCann, P., Hogg, R. E., Fallis, R., & Azuara‐Blanco, A. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18595 · Cited by 59
“During development pipelines, 90% of drug candidates fail at some point, leaving only 10% as a marketable product.(6) Failure late in clinical development results in greater amounts of time, money, and effort invested with little or no return.”
BackgroundGenetics of Alzheimer’s Disease: the Importance of Polygenic and Epistatic Components
Raghavan, N., & Tosto, G. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0787-1 · Cited by 56
Cho, M. K., Seo, M. J., Juvekar, V., Jo, J. H., Kim, W., Choi, K. S., & Kim, H. M. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c01728 · Cited by 59
Ukelis, U., Kramer, P.-J., Olejniczak, K., & Mueller, S. O. (2008) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2008.02.002 · Cited by 57
“Nevertheless, they are still only a model and can lead to misleading results not predictive of human toxicity in particular if species-specific biotransformation determines toxicity (Kola and Landis, 2004; Olson et al., 2000).”
BackgroundThe potential of immobilized artificial membrane chromatography to predict human oral absorption
Tsopelas, F. N., Vallianatou, T., & Tsantili‐Kakoulidou, A. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.09.020 · Cited by 56
Peck, R. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.02.004 · Cited by 58
Hu, N., Wang, T., Wang, Q., Zhou, J., Zou, L., Su, K., Wu, J., & Wang, P. (2014) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2014.07.080 · Cited by 57
“However, a number of cardiovascular or non-cardiovascular agents have been withdrawn from the market due to the sudden cardiac death cases, and drug-induced cardiotoxicity became the leading cause of drug withdrawal or development termination (Kola and Landis, 2004; Bowes et al., 2012).”
BackgroundNiklas, J., Noor, F., & Heinzle, E. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.07.005 · Cited by 56
Cooper, D. L., Conder, C. M., & Harirforoosh, S. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.938046 · Cited by 68
“At present, the pharmaceutical industry is investigating altered drug delivery methods for new and currently patented drugs as a means to offset exponential cost in new drug development and prevention of attrition [149].”
BackgroundSex differences in kidney gene expression during the life cycle of F344 rats
Kwekel, J. C., Desai, V. G., Moland, C. L., Vijay, V., & Fuscoe, J. C. (2013) · Biology of Sex Differences · doi:10.1186/2042-6410-4-14 · Cited by 59
“Drug-induced kidney injury is a common reason for drug candidate failure during drug development [15].”
BackgroundLost in Translation: Neuropsychiatric Drug Development
Becker, R. E., & Greig, N. H. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000446 · Cited by 59
“These problems do not self-correct because these errors and biases are not detected in time to alter the courses of studies and interpretations of outcomes (4, 9, 11, 12).”
BackgroundInfluentialHow valid are claims for synergy in published clinical studies?
Ocaña, A., Amir, E., Yeung, C., Šeruga, B., & Tannock, I. F. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr608 · Cited by 65
Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development
Bernard, A., Kimko, H. H. C., Mital, D. P., & Poggesi, I. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.693480 · Cited by 58
“The development of new agents for oncology indications is particularly risky: the success rate for a candidate drug entering the clinical development has been reported to be 5%, approximately 50% of the average success rate in all therapeutic areas (11%) [1].”
BackgroundParadigm shift in natural product research: traditional medicine inspired approaches
Mukherjee, P. K., Bahadur, S., Harwansh, R. K., Biswas, S., & Banerjee, S. (2017) · Phytochemistry Reviews · doi:10.1007/s11101-016-9489-6 · Cited by 63
“…hecogenin [20] Aphrodisiac, immunomodulatory, anticancer Khanam et al. (2013) Cinchona officinalis L. (Rubiaceae) Cinchona Bark Quinine [21], quinidine, cinchonine and cinchonidine Used for malaria fever, indigestion, mouth and throat diseases, cancer etc. Achan et al. (2011)”
BackgroundLepri, S., Ceccarelli, M., Milani, N., Tortorella, S., Cucco, A., Valeri, A., Goracci, L., Brink, A., & Cruciani, G. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618881114 · Cited by 59
“1-Phenylphthalazine (1) was prepared by direct arylation of phthalazine with phenylboronic acid in very mild condition (20).”
BackgroundMethodAssembly of Hepatocyte Spheroids Using Magnetic 3D Cell Culture for CYP450 Inhibition/Induction
Desai, P., Tseng, H., & Souza, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051085 · Cited by 50
Matrix Factorization-based Technique for Drug Repurposing Predictions
Ceddia, G., Pinoli, P., Ceri, S., & Masseroli, M. (2020) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2020.2991763 · Cited by 57
“The challenge for new compounds is to make it to the phase II of clinical trials; only 10% pass the phase I due to safety concerns and ineffectiveness [3]–[5].”
BackgroundAppelt‐Menzel, A., Oerter, S., Mathew, S., Haferkamp, U., Hartmann, C., Jung, M., Neuhaus, W., & Pleß, O. (2020) · Current Protocols in Stem Cell Biology · doi:10.1002/cpsc.122 · Cited by 57
Drug Absorption Modeling as a Tool to Define the Strategy in Clinical Formulation Development
Kuentz, M. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9054-3 · Cited by 62
“Research-based companies have to decrease their attrition rates to cope with the situation and to retain their competitiveness (2).”
BackgroundThe art of antibody process development
Steinmeyer, D. E., & McCormick, E. L. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.04.005 · Cited by 56
Chemical representation learning for toxicity prediction
Born, J., Markert, G., Janakarajan, N., Kimber, T. B., Volkamer, A., Martínez, M. R., & Manica, M. (2023) · Digital Discovery · doi:10.1039/d2dd00099g · Cited by 63
Winter, M. J., Owen, S. F., Murray‐Smith, R., Panter, G. H., Hetheridge, M. J., & Kinter, L. B. (2010) · Integrated Environmental Assessment and Management · doi:10.1897/ieam_2009-044.1 · Cited by 62
“A review of US Food and Drug Administration (USFDA)registered compounds in 2002 revealed that, on average, new drugs took 12 years and 10 months to reach registration, at an estimated cost of about US $900 million per compound (Kola and Landis 2004).”
BackgroundFunctional assessments in repeat-dose toxicity studies: the art of the possible
Redfern, W. S., Ewart, L. C., Lainée, P., Pinches, M., Robinson, S., & Valentin, J. (2013) · Toxicology Research · doi:10.1039/c3tx20093k · Cited by 57
Dashboard Systems: Implementing Pharmacometrics from Bench to Bedside
Mould, D. R., Upton, R. N., & Wojciechowski, J. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9632-5 · Cited by 55
“Drug development costs have escalated dramatically in recent years (34) and new therapeutic drug approvals have declined (35).”
BackgroundWhat are we learning from the cancer genome?
Collisson, E. A., Cho, R. J., & Gray, J. W. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.159 · Cited by 59
Kummar, S., Doroshow, J. H., Tomaszewski, J. E., Calvert, H., Lobbezoo, M. W., & Giaccone, G. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.024 · Cited by 55
“The failure rate for new oncology drugs is currently over 90% (4).”
BackgroundBrennan, M. Á., Renaud, A., Gamblin, A.-L., d’Arros, C., Nédellec, S., Trichet, V., & Layrolle, P. (2015) · Biomedical Materials · doi:10.1088/1748-6041/10/4/045019 · Cited by 61
“Indeed, the attrition rate for new drug therapies after entering clinical development is approximately 90% despite the enormous investment (~1 billion dollars/drug) in development and screening [2, 3].”
BackgroundWang, J., Ye, C., Zhu, B., Zhou, C., & Mei, X. (2014) · CrystEngComm · doi:10.1039/c4ce02044h · Cited by 55
Molecular‐based diagnosis of multiple sclerosis and its progressive stage
Barbour, C. R., Kosa, P. F., Komori, M., Tanigawa, M., Masvekar, R., Wu, T., Johnson, K. R., Douvaras, P., Fossati, V., Herbst, R., et al. (2017) · Annals of Neurology · doi:10.1002/ana.25083 · Cited by 60
A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials
Grayling, M. J., Dimairo, M., Mander, A., & Jaki, T. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz126 · Cited by 55
“Kola and Landis (52) highlighted that 60% of regimens that had “promising” activity in single-arm phase II trials failed to demonstrate superiority in phase III.”
Sköld, C., Winiwarter, S., Wernevik, J., Bergström, F., Engström, L., Allen, R., Box, K. J., Comer, J. E. A., Mole, J., Hallberg, A., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0506219 · Cited by 55
Impact of Biopharmaceutics Classification System-Based Biowaivers
Cook, J., Davit, B. M., & Polli, J. E. (2010) · Molecular Pharmaceutics · doi:10.1021/mp1001747 · Cited by 56
Banks, W. A., & Greig, N. H. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0436 · Cited by 51
Raising the bar for cancer therapy models
Francia, G., & Kerbel, R. S. (2010) · Nature Biotechnology · doi:10.1038/nbt0610-561 · Cited by 54
The Current State of Drug Discovery and a Potential Role for NMR Metabolomics
Powers, R. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401803b · Cited by 62
Pharmacology of Metabotropic Glutamate Receptor Allosteric Modulators
Gregory, K. J., Noetzel, M. J., & Niswender, C. M. (2013) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-394587-7.00002-6 · Cited by 58
Cardiomyocytes derived from human pluripotent stem cells for drug screening
Zeevi‐Levin, N., Itskovitz‐Eldor, J., & Binah, O. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.01.005 · Cited by 60
An industry perspective on the role and utility of animal models of pain in drug discovery
Whiteside, G. T., Pomonis, J. D., & Kennedy, J. D. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.08.033 · Cited by 59
Nadanaciva, S., Aleo, M. D., Strock, C. J., Stedman, D. B., Wang, H., & Will, Y. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.06.019 · Cited by 54
Discovery of a new HIV-1 inhibitor scaffold and synthesis of potential prodrugs of indazoles
Kim, S.-H., Markovitz, B., Trovato, R., Murphy, B. R., Austin, H., Willardsen, A. J., Baichwal, V. R., Morham, S. G., & Bajji, A. C. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.075 · Cited by 54
Slater, T., Bouton, C. M. L. S., & Huang, E. S. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.01.008 · Cited by 54
Microdosing: A Critical Assessment of Human Data
Rowland, M. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23290 · Cited by 56
Mi, S., Yi, X., Du, Z., Xu, Y., & Sun, W. (2018) · Biofabrication · doi:10.1088/1758-5090/aaa97e · Cited by 56
Khan, T., Lawrence, A. J., Azad, I., Raza, S., Joshi, S., & Khan, A. R. (2019) · Current Computer - Aided Drug Design · doi:10.2174/1573399815666190326120006 · Cited by 57
Schuck, E. L., Bohnert, T., Chakravarty, A., Damian‐Iordache, V., Gibson, C. R., Hsu, C., Heimbach, T., Krishnatry, A. S., Liederer, B. M., Jing, L., et al. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9716-2 · Cited by 57
“Drug discovery and development has been plagued by clinical attrition rates exceeding 90%, where the primary cause was identified by Kola and Landis (6) as lack of efficacy and unexpected safety findings.”
Backgroundvan Meer, P. J. K., Graham, M. L., & Schuurman, H. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.02.055 · Cited by 65
Gendoo, D. M. A. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.01.010 · Cited by 53
“Despite advancements, poor model characterization still affects development of anticancer treatments, and attributes to only a small percent of potential drugs passing FDA approval at the clinical stage [62– 64].”
BackgroundDevelopment of QSAR models to predict blood-brain barrier permeability
Faramarzi, S., Kim, M. T., Volpe, D. A., Cross, K. P., Chakravarti, S., & Stavitskaya, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1040838 · Cited by 57
“Investigation of BBB permeability is essential when evaluating the abuse potential of new pharmaceuticals and designing CNS drugs, as only 2% of small molecules cross the BBB (Kola and Landis, 2004; Pardridge, 2005).”
BackgroundShaffer, C. L. (2010) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(10)45004-6 · Cited by 62
Benbow, J. W., Aubrecht, J., Banker, M. J., Nettleton, D. O., & Aleo, M. D. (2010) · Toxicology Letters · doi:10.1016/j.toxlet.2010.05.016 · Cited by 55
Predicting therapeutic efficacy — Experimental pain in human subjects
Chizh, B. A., Priestley, T., Rowbotham, M. C., & Schaffler, K. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.12.016 · Cited by 58
Strategies to optimize the brain availability of central nervous system drug candidates
Wager, T. T., Villalobos, A., Verhoest, P. R., Hou, X., & Shaffer, C. L. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.564158 · Cited by 52
“Unfortunately, recent neuroscience drug discovery efforts have yielded fewer new chemical entities launched into the US market than in previous decades, despite considerable research efforts and clear unmet medical needs [1,2].”
BackgroundUpdate Information on Drug Metabolism Systems— 2009, Part I
Guengerich, F. P., & Rendić, S. (2010) · Current Drug Metabolism · doi:10.2174/138920010791110908 · Cited by 53
“Although the field is highly developed and the fraction of drug candidate attrition due to problems with human pharmacokinetics has decreased [11], in vitro/in vivo discrepancies are still an issue [12, 13].”
BackgroundPhase 0 Microdosing PET Study Using the Human Mini Antibody F16SIP in Head and Neck Cancer Patients
Heuveling, D. A., de Bree, R., Vugts, D. J., Huisman, M. C., Giovannoni, L., Hoekstra, O. S., Leemans, C. R., Neri, D., & van Dongen, G. A. M. S. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.111310 · Cited by 49
“Information from microdosing (phase 0) PET studies may contribute to more clever drug selection in early clinical development, with the intention of improving the success rate once a new drug is entering clinical trials (12,13).”
BackgroundFreyer, N., Knöspel, F., Strahl, N., Amini, L., Schrade, P., Bachmann, S., Damm, G., Seehofer, D., Jacobs, F., Monshouwer, M., et al. (2016) · BioResearch Open Access · doi:10.1089/biores.2016.0027 · Cited by 50
“During drug development, only one out of nine compounds gets approved by the regulatory authorities, usually due to a lack of efficacy or toxic side effects.(1) Thus, models for assessment of drug toxicity, especially hepatotoxicity, in the early phase of drug development are needed.”
BackgroundYamamoto, Y., Danhof, M., & de Lange, E. C. M. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0050-3 · Cited by 58
“However, development of CNS drugs is one of the most challenging tasks for the pharmaceutical industry (1).”
BackgroundKundu, A., McCoy, L., Azim, N., Nguyen, H. T., Didier, C. M., Ausaf, T., Sharma, A. D., Curley, J. L., Moore, M. J., & Rajaraman, S. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01184 · Cited by 55
Pharmaceutical Perspectives of Nonlinear QSAR Strategies
Michielan, L., & Moro, S. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100072z · Cited by 64
Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety
Wang, J., Urbán, L., & Bojanic, D. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.5.641 · Cited by 59
“This is at least in part attributed to the high attrition rate of drug candidates in development [4-6] .”
BackgroundResultEvidence from Toxicology: The Most Essential Science for Prevention
Mandrioli, D., & Silbergeld, E. K. (2015) · Environmental Health Perspectives · doi:10.1289/ehp.1509880 · Cited by 56
“These failures may result in costs of millions of dollars in develop ment as well as harms to patients (Kola and Landis 2004).”
BackgroundUetrecht, J. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600959615 · Cited by 52
“As companies became better at dealing with other issues, such as unsuitable pharmacokinetic properties, toxicity has become a major source of drug candidate failure (Kola and Landis, 2004).”
BackgroundColorectal cancer models for novel drug discovery
Golovko, D. M., Kedrin, D., Yilmaz, Ö. H., & Roper, J. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1079618 · Cited by 65
“However, of candidate therapies selected for clinical trials based on encouraging preclinical data, only approximately 5% demonstrate clinical efficacy in Phase III trials [2].”
BackgroundFowler, C. J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.02.005 · Cited by 54
Wang, J., Yu, X., Zhou, C., Lin, Y., Chen, C., Pan, G., & Mei, X. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.01.022 · Cited by 52
Wittig, A., Collette, L., Appelman, K., Bührmann, S., Jäckel, M. C., Jöckel, K., Schmid, K. W., Ortmann, U., Moss, R., & Sauerwein, W. A. G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00856.x · Cited by 57
“Similar trial designs were recently allowed by the Exploratory Investigational New Drug guidance [11] by the U.”
MethodLaunching invasive, first‐in‐human trials against Parkinson's disease: Ethical considerations
Kimmelman, J., London, A. J., Ravina, B. M., Ramsay, T., Bernstein, M., Fine, A., Stahnisch, F. W., & Emborg, M. E. (2009) · Movement Disorders · doi:10.1002/mds.22712 · Cited by 57
Metabolomics for Early Detection of Drug-Induced Kidney Injury: Review of The Current Status
Boudonck, K. J., Rose, D. J., Karoly, E. D., Lee, D. P., Lawton, K. A., & Lapinskas, P. J. (2009) · Bioanalysis · doi:10.4155/bio.09.142 · Cited by 54
Sanoh, S., Naritomi, Y., Fujimoto, M., Sato, K., Kawamura, A., Horiguchi, A., Sugihara, K., Kotake, Y., Ohshita, H., Tateno, C., et al. (2015) · Xenobiotica · doi:10.3109/00498254.2015.1007112 · Cited by 55
“However, discontinuation because of insufficient efficacy still exists (Arrowsmith, 2011; Kola & Landis, 2004).”
BackgroundCooper, T. W. J., Campbell, I. B., & Macdonald, S. J. F. (2010) · Angewandte Chemie · doi:10.1002/ange.201002238 · Cited by 52
Qiu, X., Zhang, Y., Liu, T., Shen, H., Xiao, Y., Bourner, M. J., Pratt, J. R., Thompson, D. C., Marathe, P., Humphreys, W. G., et al. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00659 · Cited by 52
Abou-Gharbia, M. A., & Childers, W. E. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401564r · Cited by 58
Trask, O. J., Moore, A., & LeCluyse, E. L. (2014) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2013.525 · Cited by 53
Zhou, R., Xu, A., Gingold, J. A., Strong, L. C., Zhao, R., & Lee, D. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.07.004 · Cited by 56
El‐Kattan, A. F., & Varma, M. V. S. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.080044 · Cited by 55
Innovation crisis in the pharmaceutical industry? A survey
Laermann-Nguyen, U., & Backfisch, M. (2021) · SN Business & Economics · doi:10.1007/s43546-021-00163-5 · Cited by 55
“2005; Kola and Landis 2004; Munos 2009).”
BackgroundThe gold industry standard for risk and cost of drug and vaccine development revisited
Pronker, E. S., Weenen, T. C., Commandeur, H. R., Osterhaus, A. D. M. E., & Claassen, H. J. H. M. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.06.051 · Cited by 56
Acute oral toxicity ofPereskia bleoandPereskia grandifoliain mice
Malek, S. N. A., Sinniah, S. K., Kim, K. H., Norhanom, A., & Sim, K. S. (2010) · Pharmacognosy Magazine · doi:10.4103/0973-1296.59969 · Cited by 67
“models have a good predictability for human toxicities of around 70-80%.[14,15] Generally, it is possible to get the fi rst hints on complex toxicities by applying in vivo methods, as information on some toxic manifestations cannot be assessed by in vitro cytotoxicity methods.”
Capriles, P. V. Z., Guimarães, A. C., Otto, T. D., de Miranda, A. B., Dardenne, L. E., & Degrave, W. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-610 · Cited by 55
“The efforts to isolate, purify, characterise, and synthesise active compounds and perform pre-and clinical tests take many years and can cost billions of dollars [17,18].”
BackgroundKrishnan, S., Hvastkovs, E. G., Bajrami, B., Choudhary, D., Schenkman, J. B., & Rusling, J. F. (2008) · Analytical Chemistry · doi:10.1021/ac800763r · Cited by 53
LaPlante, S. R., Aubry, N., Bolger, G. T., Bonneau, P. R., Carson, R. J., Coulombe, R., Sturino, C. F., & Beaulieu, P. L. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4008714 · Cited by 52
Human Astrocytes Exhibit Tumor Microenvironment-, Age-, and Sex-Related Transcriptomic Signatures
Krawczyk, M. C., Haney, J. R., Pan, L., Caneda, C., Khankan, R. R., Reyes, S. D., Chang, J. W., Morselli, M., Vinters, H. V., Wang, A. C., et al. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.0407-21.2021 · Cited by 50
Fast-Fed Variability: Insights into Drug Delivery, Molecular Manifestations, and Regulatory Aspects
Rangaraj, N., Sampathi, S., Junnuthula, V., Kolimi, P., Mandati, P., Narala, S., Nyavanandi, D., & Dyawanapelly, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091807 · Cited by 53
“In a report by Kola and Landis, it was evident that there was substantial reduction in attrition rate due to PK/bioavailability between 1991 to 2000 [180].”
BackgroundAmbreen, S., Umar, M., Noor, A., Jain, H., & Ali, R. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117164 · Cited by 53
Asplund, A., Pradip, A., Giezen, M. V., Aspegren, A., Choukair, H., Rehnström, M., Jacobsson, S., Ghosheh, N., Hajjam, D. E., Holmgren, S., et al. (2015) · Stem Cell Reviews and Reports · doi:10.1007/s12015-015-9621-9 · Cited by 64
“Hepatotoxicity is a major concern in drug discovery and development and early detection of such problems would decrease costs and improve patient safety [1, 2].”
BackgroundSmith, S. J., Wilson, M., Ward, J. H., Rahman, C. V., Peet, A. C., Macarthur, D., Rose, F. R. A. J., Grundy, R. G., & Rahman, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052335 · Cited by 56
“Food and Drug Administration, representing a huge financial and clinical burden [2,3].”
BackgroundAdvances in computationally modeling human oral bioavailability
Wang, J., & Hou, T. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.001 · Cited by 51
Krishna, R., Herman, G. A., & Wagner, J. A. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9041-8 · Cited by 55
“ment is that only ~11% of all new mechanisms are pharmacologically viable (1) and enter clinical development, highlighting the need for efficient use of biomarkers in”
BackgroundInfluentialFaratian, D., Sims, A. H., Mullen, P., Kay, C., Um, I., Langdon, S. P., & Harrison, D. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023772 · Cited by 63
“At worst, mechanisms such as unintended negative feedback contribute to the poor efficacy of agents when studied in Phase II and Phase III cancer trials and the high rate of attrition of drugs (approximately 30% due to efficacy), which is both time consuming and expensive [38].”
BackgroundSaha, S. K., Roy, S., & Khuda‐Bukhsh, A. R. (2015) · Journal of Chinese Integrative Medicine · doi:10.1016/s2095-4964(15)60201-1 · Cited by 51
U.S. Food and Drug Administration
Dolin, G. (2016) · CRC Press eBooks · doi:10.1201/b19633-9 · Cited by 51
Systems pharmacology of hepatic metabolism in zebrafish larvae
van Wijk, R. C., Krekels, E. H. J., Hankemeier, T., Spaink, H. P., & van der Graaf, P. H. (2016) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2017.04.003 · Cited by 59
“because of lack of efficacy and safety [1,2].”
BackgroundRobinson, J. R., Denny, J. C., Roden, D. M., & Driest, S. L. V. (2017) · Clinical and Translational Science · doi:10.1111/cts.12522 · Cited by 53
Metadata
- Authors
- Kola, I., & Landis, J.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Kola, Ismail
- ORCID
- Landis, John
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-08
- Volume
- 3
- Issue
- 8
- Pages
- 711-716
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1895993106
- Cited by
- 4,167
- References
- 7
- Citations by year
- 2026: 121 · 2025: 129 · 2024: 126 · 2023: 159 · 2022: 165 · 2021: 188 · 2020: 179 · 2019: 203 · 2018: 183 · 2017: 194 · 2016: 256 · 2015: 294 · 2014: 279 · 2013: 307 · 2012: 300
- FWCI
- 199.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Keywords
- pharmaceutical industry, attrition rates, R&D productivity, drug development costs, health care cost containment, drug costs, R&D investment
- MeSH terms
- Clinical Trials as Topic, Drug Industry, Humans, Pharmacokinetics, Drug Design, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.